News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioPartners Holdings AG Submits Its Novel Interferon beta-1a, Biferonex(R), To The EMEA



8/20/2007 11:46:58 AM

BAAR, Switzerland--(BUSINESS WIRE)--Biopartners Holdings AG today announced that it has submitted a marketing authorization application for Biferonex® (interferon beta-1a) to the EMEA. Biferonex represents a fully innovative, pH neutral and human serum albumin (HSA) free formulation providing an optimized interferon beta treatment solution for patients suffering from relapsing remitting multiple sclerosis (RRMS).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES